-
- Murali M. Yallapu
- Authors' Affiliations: 1Cancer Biology Research Center; 2Methodology and Data Analysis Center, Sanford Research/University of South Dakota; and 3OB/GYN, Basic Biomedical Science Division, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota
-
- Mara C. Ebeling
- Authors' Affiliations: 1Cancer Biology Research Center; 2Methodology and Data Analysis Center, Sanford Research/University of South Dakota; and 3OB/GYN, Basic Biomedical Science Division, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota
-
- Sheema Khan
- Authors' Affiliations: 1Cancer Biology Research Center; 2Methodology and Data Analysis Center, Sanford Research/University of South Dakota; and 3OB/GYN, Basic Biomedical Science Division, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota
-
- Vasudha Sundram
- Authors' Affiliations: 1Cancer Biology Research Center; 2Methodology and Data Analysis Center, Sanford Research/University of South Dakota; and 3OB/GYN, Basic Biomedical Science Division, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota
-
- Neeraj Chauhan
- Authors' Affiliations: 1Cancer Biology Research Center; 2Methodology and Data Analysis Center, Sanford Research/University of South Dakota; and 3OB/GYN, Basic Biomedical Science Division, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota
-
- Brij K. Gupta
- Authors' Affiliations: 1Cancer Biology Research Center; 2Methodology and Data Analysis Center, Sanford Research/University of South Dakota; and 3OB/GYN, Basic Biomedical Science Division, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota
-
- Susan E. Puumala
- Authors' Affiliations: 1Cancer Biology Research Center; 2Methodology and Data Analysis Center, Sanford Research/University of South Dakota; and 3OB/GYN, Basic Biomedical Science Division, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota
-
- Meena Jaggi
- Authors' Affiliations: 1Cancer Biology Research Center; 2Methodology and Data Analysis Center, Sanford Research/University of South Dakota; and 3OB/GYN, Basic Biomedical Science Division, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota
-
- Subhash C. Chauhan
- Authors' Affiliations: 1Cancer Biology Research Center; 2Methodology and Data Analysis Center, Sanford Research/University of South Dakota; and 3OB/GYN, Basic Biomedical Science Division, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota
説明
<jats:title>Abstract</jats:title> <jats:p>Curcumin (CUR), a naturally occurring polyphenol derived from the root of Curcuma longa, has showed potent anticancer and cancer prevention activity in a variety of cancers. However, the clinical translation of CUR has been significantly hampered due to its extensive degradation, suboptimal pharmacokinetics, and poor bioavailability. To address these clinically relevant issues, we have developed a novel CUR-loaded magnetic nanoparticle (MNP-CUR) formulation. Herein, we have evaluated the in vitro and in vivo therapeutic efficacy of this novel MNP-CUR formulation in pancreatic cancer. Human pancreatic cancer cells (HPAF-II and Panc-1) exhibited efficient internalization of the MNP-CUR formulation in a dose-dependent manner. As a result, the MNP-CUR formulation effectively inhibited growth of HPAF-II and Panc-1 cells in cell proliferation and colony formation assays. The MNP-CUR formulation suppressed pancreatic tumor growth in an HPAF-II xenograft mouse model and improved the survival of mice by delaying tumor growth. The growth-inhibitory effect of MNP-CUR formulation correlated with the suppression of proliferating cell nuclear antigen (PCNA), B-cell lymphoma-extra large (Bcl-xL), induced myeloid leukemia cell differentiation protein (Mcl-1), cell surface–associated Mucin 1 (MUC1), collagen I, and enhanced membrane β-catenin expression. MNP-CUR formulation did not show any sign of hemotoxicity and was stable after incubation with human serum proteins. In addition, the MNP-CUR formulation improved serum bioavailability of CUR in mice up to 2.5-fold as compared with free CUR. Biodistribution studies show that a significant amount of MNP-CUR formulation was able to reach the pancreatic xenograft tumor(s), which suggests its clinical translational potential. In conclusion, this study suggests that our novel MNP-CUR formulation can be valuable for the treatment of pancreatic cancer. Mol Cancer Ther; 12(8); 1471–80. ©2013 AACR.</jats:p>
収録刊行物
-
- Molecular Cancer Therapeutics
-
Molecular Cancer Therapeutics 12 (8), 1471-1480, 2013-08-01
American Association for Cancer Research (AACR)
